Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2005

View Archived Issues

Nimotuzumab reported to increase response to radiotherapy in nasopharyngeal carcinoma

New data from the STRIDE-4 trial supports the use of Thelin in PAH

Mologen and IDRI sign collaboration agreement

NDA submission for Seasonique extended-cycle oral contraceptive

USAMRIID awards grant to Lexicon for ricin biodefense efforts

Novartis ramps up Coartem production

Phase III trial for Remoxy

Enrollment completed in phase II congestive heart failure study of oxypurinol

Liposomes for use as contrast medium

Kinase inhibitors claimed by Merck

Scientists at Kyorin prepare and test a series of immunosuppressants

Novel PDE4 inhibitors in early development at Memory

Agents for migraine described by Lilly

Synthesis and biological activity of YM-92088, a novel nonsteroidal androgen receptor antagonist

Insmed completes SomatoKine NDA

Neuro3d completes third round of financing to fund pipeline development

New River and Shire sign letter of intent for ADHD drug NRP-104

Matriptase inhibitor suppresses androgen-independent prostate cancer in vitro and in vivo

Donepezil reported to improve cognition and memory in early-stage Alzheimer's disease

Update on the effects and safety of ABI-007 in breast cancer

Characterization of novel, selective phosphodiesterase type 7 inhibitor BRL-50481

AEE-788 shows promise in the treatment of breast cancer

Novel H3 antagonist demonstrates wake-promoting effects

Heparin sulphate mimetics prolong survival of laboratory animals with prion diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...